NASDAQ:NVAX Novavax (NVAX) Stock Price, News & Analysis $9.21 +0.23 (+2.56%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$9.20 -0.01 (-0.05%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Novavax Stock (NASDAQ:NVAX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Novavax alerts:Sign Up Key Stats Today's Range$8.92▼$9.2350-Day Range$7.70▼$10.6452-Week Range$6.13▼$11.97Volume4.42 million shsAverage Volume5.47 million shsMarket Capitalization$1.51 billionP/E RatioN/ADividend YieldN/APrice Target$12.13Consensus RatingHold Company Overview Novavax, Inc. is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses. The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus. In addition to its COVID-19 vaccine, Novavax is advancing candidates targeting respiratory syncytial virus (RSV) and seasonal influenza. These programs leverage the same nanoparticle and adjuvant technologies to address ongoing unmet needs in respiratory infectious disease. Novavax operates globally, with research and development facilities in North America and manufacturing partnerships in Europe, Asia and Africa. Collaborations with organizations such as the Serum Institute of India and SK bioscience support its ability to supply vaccines in diverse markets. This international footprint enables the company to respond rapidly to public health emergencies and to pursue broad distribution of its products. Under the leadership of President and Chief Executive Officer John C. Jacobs, who joined the company in 2021, Novavax has focused on scaling manufacturing capacity and securing regulatory approvals for its vaccine candidates. The company’s executive team and board include experienced professionals from the vaccine and biopharmaceutical industries, guiding its efforts to expand the global reach of its proprietary vaccine platform.AI Generated. May Contain Errors. Read More Novavax Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreNVAX MarketRank™: Novavax scored higher than 36% of companies evaluated by MarketBeat, and ranked 691st out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingNovavax has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 4 sell ratings.Upside PotentialNovavax has a consensus price target of $12.13, representing about 31.7% upside from its current price of $9.21.Amount of Analyst CoverageNovavax has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Novavax's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Novavax are expected to decrease in the coming year, from ($0.20) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novavax is -15.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Novavax is -15.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Novavax's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted30.39% of the float of Novavax has been sold short.Short Interest Ratio / Days to CoverNovavax has a short interest ratio ("days to cover") of 17.25, which indicates bearish sentiment.Change versus previous monthShort interest in Novavax has recently increased by 6.77%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNovavax does not currently pay a dividend.Dividend GrowthNovavax does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.27 News SentimentNovavax has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Novavax this week, compared to 8 articles on an average week.Search Interest28 people have searched for NVAX on MarketBeat in the last 30 days. This is an increase of 56% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Novavax to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novavax insiders have not sold or bought any company stock.Percentage Held by Insiders1.00% of the stock of Novavax is held by insiders.Percentage Held by Institutions53.04% of the stock of Novavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Novavax's insider trading history. Receive NVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVAX Stock News HeadlinesNovavax (NASDAQ:NVAX) Lowered to "Sell" Rating by Wall Street ZenMay 23 at 1:19 AM | americanbankingnews.comNovavax Updates Pediatric COVID-19 Vaccine Trial: What Investors Should WatchMay 22 at 12:30 PM | tipranks.comPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect.May 24 at 1:00 AM | Weiss Ratings (Ad)Novavax (NASDAQ:NVAX) Stock Crosses Above 200 Day Moving Average - What's Next?May 21 at 2:19 AM | americanbankingnews.com3 Small-Cap Stocks That Fall ShortMay 18, 2026 | finance.yahoo.comAssessing Novavax (NVAX) Valuation As Trading Swings Revive Investor InterestMay 18, 2026 | finance.yahoo.comGoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo Shares Plummet, What You Need To KnowMay 17, 2026 | finance.yahoo.comNovavax, Inc. (NVAX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comSee More Headlines NVAX Stock Analysis - Frequently Asked Questions How have NVAX shares performed this year? Novavax's stock was trading at $6.72 at the start of the year. Since then, NVAX stock has increased by 37.1% and is now trading at $9.21. How were Novavax's earnings last quarter? Novavax, Inc. (NASDAQ:NVAX) posted its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.19. Novavax's revenue was down 79.0% on a year-over-year basis. Read the conference call transcript. When did Novavax's stock split? Shares of Novavax reverse split on Friday, May 10th 2019.The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Novavax's major shareholders? Novavax's top institutional investors include Shah Capital Management (9.11%), Bank of America Corp DE (4.04%), TSP Capital Management Group LLC (0.85%) and Bank of New York Mellon Corp (0.47%). Insiders that own company stock include James F Young, Filip Dubovsky and Rachel K King. View institutional ownership trends. How do I buy shares of Novavax? Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novavax own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novavax investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Moderna (MRNA), Advanced Micro Devices (AMD), Pfizer (PFE) and Alibaba Group (BABA). Company Calendar Last Earnings5/06/2026Today5/24/2026Jefferies Global Healthcare Conference 20266/04/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 NVAX's financial health is in the Green zone, according to TradeSmith. NVAX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:NVAX CIK1000694 Webwww.novavax.com Phone(240) 268-2000Fax240-268-2100Employees1,990Year Founded1987Price Target and Rating Average Price Target for Novavax$12.13 High Price Target$19.00 Low Price Target$6.00 Potential Upside/Downside+31.7%Consensus RatingHold Rating Score (0-4)2.10 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$440.30 million Net Margins-14.73% Pretax Margin-14.45% Return on Equity-14.82% Return on Assets1.23% Debt Debt-to-Equity RatioN/A Current Ratio2.48 Quick Ratio2.45 Sales & Book Value Annual Sales$1.12 billion Price / Sales1.35 Cash Flow$3.52 per share Price / Cash Flow2.62 Book Value($0.88) per share Price / Book-10.47Miscellaneous Outstanding Shares164,440,000Free Float162,794,000Market Cap$1.51 billion OptionableOptionable Beta2.37 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:NVAX) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour computer is about to become a museum pieceFor 67 years, chip-making meant slicing a single silicon wafer into hundreds of pieces. Three companies just a...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novavax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
